Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 452 participants.

Also called NCT06196320

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 452 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06196320
Other papers using this trial's data
  • Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial Stroke and vascular neurology, 2026-06-29 DOI, PubMed 41151803, PMC13347805 In the PMC Open Access subset under CC BY-NC.
  • Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial Lancet (London, England), 2026-02-21 DOI, PubMed 41655588

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06196320. Randomized; single masking; primary purpose treatment. Start 2024-01-24 (actual); primary completion 2025-09-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
Acronym
TRACE-5
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Best Practice (which may include intravenous Alteplase)
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct06196320
Content hash
9e8a3ac7b8c572b7a14d07edf906a122731955be25fea7fdeded0aaa9355f614